𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rationale and clinical experience with epidermal growth factor receptor inhibitors in gynecologic malignancies

✍ Scribed by Ami P. Vaidya; Aric D. Parnes; Michael V. Seiden

Book ID
107531903
Publisher
Springer
Year
2005
Tongue
English
Weight
339 KB
Volume
6
Category
Article
ISSN
1527-2729

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Clinical implications of the mechanism o
Clinical implications of the mechanism of epidermal growth factor receptor inhibitors
✍ John Marshall πŸ“‚ Article πŸ“… 2006 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 2 views

## Abstract Novel therapeutic agents that target the epidermal growth factor receptor (EGFR) constitute an important addition to the therapeutic armamentarium for the treatment of metastatic disease. EGFR‐targeted agents currently approved by the U.S. Food and Drug Administration include cetuximab,

Epidermal growth factor-related peptides
Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate
✍ E. R. Sherwood; C. Lee πŸ“‚ Article πŸ“… 1995 πŸ› Springer-Verlag 🌐 English βš– 831 KB

Epidermal growth factor (EGF) and transforming growth factor-alpha (TGFo0 are two closely related peptides that interact with cell-surface epidermal growth factor receptors (EGFR) to induce receptor tyrosine phosphorylation and activation of intracellular signal-transduction pathways. EGF appears to